Unlock instant, AI-driven research and patent intelligence for your innovation.

Kit for predicting curative effect of immune checkpoint inhibitor of non-small cell lung cancer patient

A non-small cell lung cancer, immune checkpoint technology, applied in the field of biomedical testing, can solve problems such as difficulty in comparison and standardization, and inability to thoroughly distinguish between actual responders and non-responders

Pending Publication Date: 2022-06-03
ZHONGSHAN HOSPITAL FUDAN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The high expression of PD-L1 is closely related to the efficacy of anti-PD-1 therapy, but the actual responders and non-responders in anti-PD-1 therapy cannot be completely distinguished
At the same time, IHC-based PD-L1 detection has high heterogeneity among different diagnostic antibodies (28-8, 22C3, SP142, SP263, etc.) and tumor tissues, making it difficult to compare and standardize

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Kit for predicting curative effect of immune checkpoint inhibitor of non-small cell lung cancer patient
  • Kit for predicting curative effect of immune checkpoint inhibitor of non-small cell lung cancer patient

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] A) Sample collection:

[0024] From July 2019 to August 2021, 33 NSCLC patients were recruited in the Department of Respiratory Medicine, Zhongshan Hospital, Fudan University. Baseline peripheral blood was collected from each patient prior to administration of anti-PD-1 / PD-L1 inhibitors.

[0025] The patient's venous blood is collected, and the blood collection tube is gently inverted and mixed 5-10 times immediately after blood collection to ensure that the anticoagulant works. Try centrifuging the blood samples at 2000rpm for 10 minutes after blood collection, separating the plasma and placing it in a cryovial, frozen at -80°C until analysis and use.

[0026] B) Patient Definition:

[0027] Basic clinical information for each patient was recorded, including age at the time of treatment, sex, tumor histological type, performance status score, eighth edition TNM staging, date of disease progression, and date of death. The follow-up period ended on January 29, 2022. ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of any one or more of SAA1 protein, SAA2 protein, S100A8 protein and S100A9 protein in predicting the curative effect of an immune checkpoint inhibitor of a non-small cell lung cancer patient, and a kit for predicting the curative effect of the immune checkpoint inhibitor of the non-small cell lung cancer patient. Comprising one or more of an SAA1 protein detection reagent, an SAA2 protein detection reagent, an S100A8 protein detection reagent and an S100A9 protein detection reagent. The combination of one or more of SAA1, SAA2, S100A8 and S100A9 proteins is used as a therapeutic effect related biomarker for the non-small cell lung cancer patient receiving immune checkpoint inhibitor treatment, and a reliable prediction tool is provided for whether the non-small cell lung cancer patient is subjected to immune checkpoint inhibitor treatment or not.

Description

technical field [0001] The invention relates to the technical field of biomedical detection, in particular to a kit for predicting the efficacy of an immune checkpoint inhibitor in patients with non-small cell lung cancer. Background technique [0002] Despite the clinical benefit of immune checkpoint inhibitor (ICIs) therapy, only about one-quarter of non-small cell lung cancer (NSCLC) patients respond to ICIs therapy and have long-term clinical benefit. Predict the efficacy of ICIs treatment, find benefit groups, improve treatment response and overall prognosis. So far, there are no fully reliable biomarkers in clinical practice to determine the therapeutic response of NSCLC patients against programmed cell death protein 1 and its ligand (PD-1 / PD-L1) inhibitors. To save patients from ineffective treatment, biomarkers that can accurately predict efficacy are urgently needed in clinical practice. [0003] Detection of PD-L1 expression on tumor cells by immunohistochemical ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574G01N33/68
CPCG01N33/57423G01N33/57488G01N33/68G01N2800/52G01N2333/775G01N2333/4727
Inventor 赵彦程许书榕宋元林
Owner ZHONGSHAN HOSPITAL FUDAN UNIV